UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 29, 2006

CYCLACEL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware	**0-50626**	**91-1707622**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

150 John F. Kennedy Parkway, Suite 100
Short Hills, NJ 07078
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (973) 847-5955

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

Attached as Exhibit 99.1 is a copy of a press release issued by Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the "**Company**"), dated June 29, 2006, announcing that the Company has begun a Phase IIb randomized trial of seliciclib for previously treated non-small cell lung cancer.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

Number	Description
99.1	Press release dated June 29, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CYCLACEL PHARMACEUTICALS, INC.

Dated: July 7, 2006

By: /s/ Paul McBarron
Name: Paul McBarron
Title: Executive Vice President, Finance & Chief Operating Officer

PRESS RELEASE

Cyclacel Pharmaceuticals, Inc.

CYCLACEL BEGINS A PHASE IIb RANDOMIZED TRIAL OF SELICICLIB FOR PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER

SHORT HILLS, NJ, June 29, 2006 – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that the company is beginning a Phase IIb, multi-center, randomized, double-blinded trial to evaluate the efficacy and safety of the investigational drug seliciclib (CYC202), an orally available molecule that targets cyclin dependent kinases (CDKs), as a third line treatment in patients with non-small cell lung cancer (NSCLC). The trial is being initiated following Food and Drug Administration (FDA) and central Institutional Review Board (IRB) approval of the trial protocol. The ''APPRAISE'' study builds on the observation of prolonged stable disease experienced by heavily-pretreated NSCLC patients enrolled in a Phase I study of single agent seliciclib.

The study is co-chaired by Chandra P. Belani, M.D., Professor of Medicine and Co-Director of the Lung and Thoracic Program at the University of Pittsburgh Cancer Institute in Pittsburgh, PA and Alan B. Sandler, M.D., Associate Professor of Medicine at the Vanderbilt-Ingram Cancer Center in Nashville, TN. Approximately 160 patients from 20 centers in the United States will participate in the study. The trial's primary efficacy endpoint is progression free survival. Secondary endpoints include overall survival, response rate, response duration, safety and tolerability. The study employs a randomized discontinuation design. All patients will receive seliciclib for at least three treatment cycles. Patients who achieve stable disease after three cycles will be randomized to continue on seliciclib or receive placebo with best supportive care. Patients in the placebo group whose disease progresses will be given the option to cross-over and receive seliciclib treatment again.

Seliciclib is an orally available cyclin dependent kinase (CDK) inhibitor that selectively inhibits multiple enzyme targets, CDK2/E, CDK2/A, CDK7 and CDK9, that are central to the process of cell division and cell cycle control. Seliciclib has been evaluated to date in approximately 240 patients, including patients with advanced NSCLC in two Phase IIa studies in which seliciclib was administered in combination with gemcitabine and cisplatin as first-line treatment and with docetaxel as second-line treatment.

''We have been interested in evaluating seliciclib, our lead cell cycle inhibitor, as a treatment for lung cancer for some time. The APPRAISE study is a key next step in our program to assess the antitumor activity of seliciclib as a monotherapy for lung cancer,'' said Spiro Rombotis, President and Chief Executive Officer of Cyclacel. ''We are also interested in evaluating seliciclib in other types of cancer, such as nasopharyngeal cancer. The seliciclib program is part of Cyclacel's strategy to develop a portfolio of cell cycle inhibitor drugs for the treatment of cancer. Our pipeline also includes sapacitabine (CYC682), an orally-available, cell cycle modulating nucleoside analog in Phase I clinical trials for the treatment of solid and hematologic cancers, and CYC116, an orally-available, Aurora kinase inhibitor in IND-directed preclinical development.''

About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. The company is currently evaluating seliciclib (CYC202), an orally available cyclin dependent kinase inhibitor, in Phase II clinical trials for the treatment of lung cancer. Sapacitabine (CYC682) is an

☑ 150 JFK Parkway, Suite 100, Short Hills, New Jersey 07078, USA Tel +1 (973) 847 5955 Fax +1 (866) 271 3466
☐ Dundee Technopole, James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382 206 067

www.cyclacel.com – info@cyclacel.com

---

orally available, cell cycle modulating nucleoside analog in Phase I clinical trials for the treatment of cancer. CYC116 is an orally available, Aurora kinase inhibitor in IND-directed preclinical development. Several additional programs are at an earlier stage.

Note: The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.

Risk Factors

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words ''may,'' ''will,'' ''would,'' ''could,'' ''should,'' ''believes,'' ''estimates,'' ''projects,'' ''potential,'' ''expects,'' ''plans,'' ''anticipates,'' ''intends,'' ''continues,'' ''forecast,'' ''designed,'' ''goal,'' or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under ''Risk Factors'' in the registration statement on Form S-4 (File No. 333-131225) and in the other reports of Cyclacel filed with the SEC.

Contacts for Cyclacel:

For Investors:
TS Communications Group, LLC(914) 921-5900
Tara Spiess / Andrea Romstad

For Media:
Feinstein Kean Healthcare:(617) 577-8110
Robert Gottlieb / Kate Weiss

---

begin 644 html_03088logo.jpg M_]C_X``02D9)1@`!`0$!(`$@``#__@`V($EM86=E(&=E;F5R871E9"!B>2!'
M3E4@1VAO``$``00#`0$`````````````!@$#!P@"!0D$"O_$`$<0 M```&`0$#"`<%!08%!0```$"`P0%!@`""!2Q4755>4EM,)(3%189+5%")!
MD=$6(S)QL0I"1W*!H1FRP<7P)38W.%+_Q``=`0$``P`"`P$`````````````` M`0(#!`@%!@<)_\0`/Q$``@$"`P4$"`,`@<`````0(#`!$$!2$&$A,Q05%A M@?
`%")3<9'#T2.2DP@5,J&QP?%"X18E4H*BLM+_V@`,`P$``A$#$0`_`/WS MNW+9BV,%54RRKR0AHU<2LN<2C@"0?10U>T5'1ZQ%T0V7J+(&A+]K00BC
MV[ZQV]$`26C*TX:G:RD^Y?"!T6;*,50:RN7QM/F MD*&;$%,-(9<-^<_[1/I^VQS?-<]V-]'&>X[9#9/9[,,RVRX?
9W8O9C83`2PR>D7TIY_B(L%LQBYTP>`6?'P)AP6S[1ZK`RQCJ1UWVK]835NPV!`02,$FE3(MZ>JR<>@OQWD&(APO[R;:@^D?
\`:%BVM7#-$F(66;;3-/1K!LYAX662.==HL5L=@-D9 M$;UD9X,`3BAM3I!M]S,/.?L%M*UU>L2S59)BYMJ,0[A5HU6
MM2XS=GM\H[3:4=%M7(Z5U#4@BQ,9//[5'6UBY:T-K`2M9=Z+"S M>F'F-I#;3C/2!4_3B#V6(NP1)-C:4I)]-EHE>LEF9!&':4&2I,U)6FPT%SIN
M6M3+J9U035L@61Z+5L]24)*Q$=U6],6'V'PV*BP.7^Y^X/C^8_KC<'Q_,?URN,^.7/:?/^!\J[C53<'Q_,?U MQN#X_F/ZY7&+GM/G_`^5*IN#X_F/ZXW!\?
S']*>A.I&WI_9'I+Q<*6X(*41,V59S,NU4626`!*?-M2KW2H75+5O45IP!'&VKJ70KNIZBD3I':H&=FI.!8R:S^MQ%7M^D%/FJ3>+%/V>UQ51BJ-J3IW0*
MQ>ZI*:;6>7F8^/M6I;NN1$-2FBAY&V':0J*KQ'T8@W;!_#1CJ+(",>XCVAV; M:+5596BU29?%6D*Q0)*5ID#9'M*B'36O.K2W5L:[%66<*
M.1^28OTG;6<;'PIBEPV%FCEP2X1L+AFF@PP"'7"R8P1+BY8HT'#?!2RMEA6^ M'&`3!I#A(NW>3?LP>B3U+(,=B,KDS/-<)-A,YDSB'-,RBP6/S%G7&R9C!DYQ
M4N483$XB9N/#G6$P<6TPDMF+Y_+G4^+S7$^:VFNP)*ZZR]JU)V[H6N6_3[5C M3_0I5EZ-ZVHU'6W9=V4M6-)QE0E+;I'./8"&C9B=LYWIW$A-
QU+K;@0E9R+D MI&U1JK`&7JK)2,)5X9_+R[Z+@*_`1CF2E)21W]F>(W]HB6LJ'HF=I$T2-@"HGF=#4=:S5< M#&FB[/:VNNGI-<.2*WWR/-
QZ`,HE.C%%,]YC/(@;21R MSNY+,SNUV=F8EF9F)+,Q)8ZDDUV.@@@P>'BP^&AC@P^'BCA@@A1(HHH8D$<4
M44:*L<<<:*J)&BJB*`J*``*V`HGI>=B752XUNLZ76G6+4JN6RSLJ3`ZUT+9: MVF+5LVR%MDYPM:C89#:)B=*G&D1TWL\8(Q.P%M)JFBY$?
M=@;H$47)M1L[;6 M>A&U+IU9M4-'KISK6*+?=0-+M0T["'S=%L.G&HFEDJO$7ZG7^KW!C#SM0FZV MN@#QXWFF35-6%=,)]FJYAG[1ZMDW2SHW-
IM1.A*V.E!JC7NC4*,5H%*_8,8 MIM^R@5R[56&H%SU*TH<1TBPCJ[=-H/0!&R: MOI2=B"/V==/]JFPZSI5/1G5ZTR-/T:E;-3+Y&6W6J:8S+F#;IZ-:7DK;K4W5
M1O/.6BKZK.Z-4IQ"RP!VUEB3KP#MK)+1UGZ6'9#Z(- M@5-KJGZ1U%C4DJT0D\GIRA(IN]\69#?L5Z?_=_P;O2![N4W=`;W^/CW?\'
MNVI[MW%ZM^[=_#^&[B_#'LW`MSMU.E^G]_'3MI=R&U`W=#[-[FP-P;CM[.8. MG2O7R'EF,[$QLW&JBO'2T>QE&"PIJ(BJRD6B+UHJ9)8I%4C*-
UTCBFH4ATQ- MP'*!BCFI2&WQLKN-LQ[L`I:GMQVIX_3HFI[G3M2OV5%L%<4CVTT1FC<%HI.G MN[6-<=H6HU,:32]F)5>5L)XT(ML X5H1-/([3*)V#R
M5TT;;%I\U'1>5E)!N\!-^M)+0JW!^0^/FP\:EGW2!K?GRZ`B_2W7GV^-OVE; M3>V1LV;'5?JUCVBM4X?3U&]V1>""YML5LO6HEJ7*0R=9H`
M50%=C5ZY**,BN6IWPMB.4#'UM7]+/L>0^@NM^T=>7^NND^G.SNUH\AJH36;9 M6VC](A$1FI-
D2J5'DX2DZ@Z:5^Q76/L$^LG'HN::TG2L%1#G@(XJB)E=%ZI M=:'J!_:#:?>+C(QTM"W?T2%/MNP/+.1>GAIB'L^L4I/Z\RU1%SQ19=2Y"KNZ MHO)'C^&?5TT!
($1-'<\;\A?VE#E/^"GMJ<@(@M]CT)Y$5P6%,%QVE-(.0$X? MQ"F"W`*X)??%/B`H@<2B$@"Z@@G>W=0;<['LZ7M\:SDD81R2*0`@:P(ZC0&_
M_D-.5M-:V_TR]*%LRZIM=3Y*,A=IJGPVD&DETUNO%@U>V.MJ#1>N,Z#0&B#^ MRN8NP:HZ75:(L$ZV8K"]9U.$>/K)*LV[QS&QKE!D[41VST?UEI&T?
H=I]KKH MM/&G*!K)IU"ZB::6)]$RD(I(UZX099:LRCR%FF;27C#*H.6R[B/DF*+UM]Y% MPW*H!D\\P=6F7I$FNQ5M]FVS;AL:V.EFV'-
H4M(;;,VF^NU)LS:SAI#"+V ME[JQJ1=HA]!GAON-FL0R82)),!65<&:[T`S7Z&(=WHF_1QAN-_\`3'9]]?"; M=_\``D1[3;N$/9O]8^S,N=W?W@2I)#!`?]-C[M#,.1Z-
\;'0;)[,%9VFZW'6M/:1O57NSUTZAS50]=BB1AXUFBC(%D&T@*>]-Z MOR)XE!>3`40FY5I*V!O#U9A*-*M$;5993]H[O_T'_(.7L,;F]@+V-ET`T'*K
MHNXH7>9K7U0;SM4L\68"R]7L;(%`9RS`3;DUTQ(HJSE(QSQ,)N)D>1K-*8,1) M>2TMOAG'&Z`A$6=C1:-);/J&"S4YQAQ/&7FQJQQ',<+&K2XI,7AL/A\.^<8?
M#QLF)QN"S+#8'!3YV<*YS'+LVR^+/82(HH\/+U;SS91=D,P.!Q!@PF2/B<4F MS>:8J2/"Y5-E68X_'8^#8[,S699[GF!V)&:1)L[M'LIM!C-A, M6#B\7B,PPT\LF[=G<.
(I\$^V,Z7*^=0*\:S7!X!$CKFM5-G2L7-;LO+<24B MWBU&Y7#@ZCM]%LEE`02^A_8G4`_2?3CPT2@NN#9%&;>LY&9E$R%36")J%,JP MJ_;GTBH02BY77?
RZ`D$J+)PW4*"'?6R%:NA^%>8K.F&IKE`0!E,/TG%*F@;B) M.2!8PQ%Q9*K[@*==PP>1;544RBC'(E,4B?"-K-Y1*8T!6=*]+CN!`TG'-W5 MTF#
(!Q`J5$$HFE,$W'!Q&0.6(4R:GB&CR^1WQ#SY=P'3A-)ZQ MAE?=%AOBSG,AI:RC9@1[MHDP2(!7M<.
(VBP\,&7PX+:1+@6(150"*`).,P@(C\TS"Q%BB92`GXN.G(.;CGT/-0LPQ: MR<3,1,FU59247*1KU)=G(1L@S779OF+Q!9J[:+K-W'"*B2IR#@J"MRP;#A[/]1_J.[?
[AW>T/P'U9ZWFN62Y=,@='CCG7B0+.@P^(,>ZA,APN^AMB M3V@-2:7M'U".H&J"VL&U?M'ZPV1Y3(B6";C*]6[!J5J19W=(9-
Y(!/S<*ALV1&U#U7TPF+)M:WK3W6 MG3%31^]T[4O;8VH-2*\ZH:UCJED7C(:+N>I,RTK+M=>GQ40I,U]*/ERU=Q-5 MA%ZE#3DHU=>DU@TWI-
ITZG-)IRN1K_3JQTJ3TZF*@HC_`.B/:3,5]:K2%<49 M@/)C&.(!PK%F;^LOV4_`/%N`=(#7+3O9ABH>'V?IN9N=V;ZN:0-JZBFU@%=/=;J_/06JU4>Q+)K%L&
[J%M; M(SAC"PC:1(]3B&7)1-UZ(_8^F-GS7'9GN*.O^I>FVT22BM]4CZM[5NT7JQ;Y M)AIK9D+?2HR`N6HFHMDFJ5'PT^W*^.UIZL*65.8231I%--
N5'TXQDAB.IYW_ M`+^?]ZJ40\U!TMJ.8M;7PKS:TO\`18[-NEC;4^/8W#:MO$-J_I!>-#[K7M8M MLG:5UGK;FB:ALD(VRDBJ_J5J)8XB!L2K!`6<=;
(AHUL,.U*6-)8I4:..2.15>.2-P5='1@ M5=&4E65@0P)!!!K#A="Z.Q150K!K11D%C\H9K1KI:*S&@<3B<3)PS&3YE1,(MF$!%&.3WE^Z.\`+NLJ:"T21231M)
[7>TDCBU66,]:A%0!2%=R981?@ M,F4"&<1RIREXB@;A.8!S()QWF``#U#N_B,'],IQ&]P?,;/-#:3:$'>&=9F)= M[?XXQTXQ-
[`7]9XGK%MVPMQ+6N+6O7I+>C'T=N.&^Q.S#8;A\'U`Y+@#FXʻ MX@_Y9P/W>6$@WPYPQ(WN#YC8XC>X/F-C7M_G\._P"'R[J5RY,/C\X_ICDP^/SC^F<>
(WN# MYC8XC>X/F-C7M_G\._X?+NI7+DP^/SC^F.3#X_./Z9QXC>X/F-CB-[@^8V-> MW^?P[_A\NZE7"D`OY[_;O_`0_$`SGECB-
[@^8V8^O^IU=TX2@C3R4RZ=6>8+ M`0$9`1#Z;DI25.W4=%:-VK0-X',BD\D`=I(%9(QD'H]^KVH<(,]67*Z[1*0?Q
M+UN^:/(R2C)>,6%O(Q4I&O")NF+]FKN!5!4GK*8BJ9CI'*<9CQ&]P?,;#*RD MJP*L#8JVA!["#8BI1UD571@Z,`RLI!5@=001H0:OXS#-XUPIU`GS5J8;V=[*
MH5A6YOTJ]69:?3BZLWHD<-7"1MP")%45"G#>`&#?PF*4P"`28Y%57 M9&"O_"Q%@?
@>7^VO(&J)-$[O&DB-)&;.@8%EY0$Y))U>7_9F+E630[T[9[8N`8YN99`I?L@J MJ$^U**))I`)E"@)8W<,54L$&\Q')1IJ3T&H&O73G4O+'&45W5#*^Y&&-B[G7
M=4=3;6PZ:UEW&6`.8?7N#YC9%KI=H#3^MR5KM+P6$-%D1%=5-)P[<*K.G"31 MFS9LVQ3N'CUXZ62;MFJ!#**J'#U`4#&+"JS$*H+,Q`55U))Y``:DF_+MTJS,
MJ*SNP1$!9F8A555%RS$Z``:DG0"IAC(K5K0E:XE.7;Q-AAB'7<-Q86B$D:[+ MI';&`AS*QL@0C@J*@CO07W"DN7[R9A#)'QF]P?,;!4J2"+$&Q!MIYO165U5U
M-U8`@CD0:OXS%=DU,J](&FHOS& MHU[->50LD;EU1U9HVW7"D'=;_I:W(]HYCD:OXRQQ&]P?,;'$;W!\QLK;S<>> MOFQJ]7\98XC>X/F-F%;EK]0Z-
8)6MS!+,X?5^$962QK0M8F9F/KT"_.5E MGC)(Y4&?$F?ECIE6,B!1%0H`&62.20[L:,YM>RBYM<"YMRU('Q-N=9RS10+O MS2)&I-MYV"B]B;7)')0S'L52>0-
9QQG6L)%M*,FX/P_O&_'U96Q&AT/?IYY^;&M`00"#<' M4$:@@\B#5_&8BK6LE8MMLFJ?!1]L=O*],R]?F98:O,)UAA,0A#*/&+BQ&3&- M37.0""T(=0IG?*I-
T(#J5)`8!M#8\C8]#TK..6.92T M3JZABI*FX#+S%^T=:OXR#7V_0&FU9>6VTJND(9BYC6JZC)JXD'`+2K]"-9@5 MJA^].4SIRD50Q?4F014-]THY,2J"8`$`#
<.X0^\;\0`0_P!AR-Q@H:WLL2`V MEB5W=X`]HWEN.EQ?G5@Z%VC#`NBJS)?VE5RP5B.QBC`J5/97T8RP)S!Z]P?
M,;,4N=9*NWU#6TP28VJ2M#0D,O(A$5F6DHJ*:3Q2C'OI26;$,T8,3<7"N[<& M(BW,!BJ&WE$,E8W>^XI;=4LUM;*+`L>P78"YZFW.JR2QQ;ID=4WW$:;Q`WG(
M)"KVL0I-AT!/(&LNXRP!S#^`?,;'&;U>H/6.[^(W^_P#VC\,IYY^?/P-:5?Q MF-=.]5:=JFRF9"FR"K]M!3;F`D!<-G+%0KUN0BH*I).`!19BZ3."C)Z0.1=$
M`XI"/`;=D/B-[@^8V69&1BKJ58"$V#$>OFQK2K^,L<1O<'S&QQ&]P?,;%O-QYZ^;&E7\98XC>X/F-CB- M[@^8V+>;CSU\V-
*OXRQQ&]P?,;'$;W!\QL6\W'GKYL:5?QECB-[@^8V.(WN# MYC8MYN//7S8TJ_C+'$;W!\QL<1O<'S&Q;S<>>OFQI5_&6.(WN#YC8XC>X/F- MBWFX\]?-
C2K^,L<1O<'S&RH*#N#U!_N/_7(I5[*#[!_D/],KE!]@_P`A_IBE M6!_B/_F'^@8SI)NR5ZMD26L,[#02+I8Z+96:E6,4DX5(F"ATD%'RZ!%E")@)
MSD3$QBD#B,`%]>1[I2TU[0J+XOK_`-0S3<=K%4T*B^+Z_]0QTI::]H5%\7U_ZACA2^[D_(WV[Q\Z< M>#WT7ZB?
>IYC('TI::]H5%\7U_ZACI2TU[0J+XOK_P!0QPI?=R?D;[=X^=./ M![Z+]1/O4\QD#Z4M->T*B^+Z_P#4,=*6FO:%1?%]?^H8X4ONY/R-]N\?.G'@
M]]%^HGWJ>9K+M"U>S6:>T)_9I&8(>)U?:2$C-Q$T MN4`N-0#<:U;TWTZAM-8-Y$1+N3DE9:=E;/.3$RNBXE)F?FE2JR$@[.V;M&Q. M,4TTD&
[=NDBV03(F0H[A,.0<@?2EIKVA47Q?7_J&.E+37M"HOB^O_4,JZSR, M7=)&9CF=M9FI[@JI8J/'RKA%8D=8I2`77<1BS4`?IJI)@
M@)>7`V;C49O%LZ;5FD)#O*]$M:]$-HZ"D&SAH_AFB#)%)*,?-W0%<)O&0%%N MZY8!447345$Z@`X];TH::=H5%\80'].)<$
MTSEHPT*F`2\T^,T,E]N!5N=M$+E=ID.E+37M"HO MB^O_`%#'2CIKVA47Q?7]_J]GKYPS-%E1T<1R75E865@="#H0-#RL>\5K*^'E MBDB,T)$B,AWF1ULP(-
U+`,-=1<7K'FS?TEAIZ)-3!FC/$I^62JZMI311MZU. M3.0D(K:DD3'X)=0H*F$%S"\Y#@^TB8>$YL_Y`@U1TT#_`!"HOB^O_4,KTI::
M]H5%\7U_ZADRB661Y."4WV+;J1L%%[:`6[Q\2;]:B!H((8H?65DX:*F_)*A= MK#FQO_@6%S6M&OT+92:BUVR:106H[?5X$(&*"'?BHX#:9S55-*.%GT1=7SI8(
M[@BR:W\5JSA6"&7$2C$QGUAE8QAT6-"+W8*&(,CW_$ M?3?W5N+@DSS&0/I2TU[0J+XOK_U#'2EIKVA47Q?7_J&8*7W/G7)X
M\'OHOU$^]3S//76NCZH26J6KTY5(2P/(%]IEI_&2[&/8`0;_`%Y&74+9D:UM]'Z#G[(`/,7!!N!7$QL>&QL2Q-B5C"N7#)(@:YC
MDC[>7XA)!N&MNL"I(,@JZ,>VKD`WB(YQ$13>$BD8V)=MU6CJ+8),D4VDT*B M^+Z_]0S`QRDD\.34WU5B=>^VO/GUY]:Y2S0*JKQH?
9`&CH!H+:#>T'=TK6G0 MZ'FJ[J]JT$U%ZJ1A;'J7>I:&*,2X2TPD(A,(`?^X97I2TU[0J+XOK_`-0S M:EX?3V.BI>I1+A:K2SYHW%-ZR
MM[T&BZ00#'C!1R8%FO(KE.)U?5PCLSTI::]H5%\7U_ZAE.E#33M"HWC"`#_N M&3"98N)^\"["6(Q'V6%@61KBP/50+=_;8U&)6#$\"^)C0P3K.I#H;LJ2)NGV@
M;2Z$:@7N+@SP/9^/X^W^>8WU>E+%$::W-Y48F1G+.,&Y8P,=%(*.'RLI+" M6+:KI))!Q\$>9V,@N?>4B:#510YBE+OS[>E+37M"HOB^O_4,H.J.FH_XA47Q
M?7_J&9HDBNC&%V"LK;I5K,`0;&PY'EXUM))"\OUY`NE#33M"HOB^O\`U#_P/5[,KTI::]H5
M%\7U_P"H9I.9IW$C0L&W55MU&LV[H&UOKN[H\`>MJQPJX;"1&&/$(T>^SH&D MCN@<[Q4;M@1O[S#0?Q6Z5$-
>X*MV&@+L+-!7B;:)RT6\8&TZ8.)"V0LPT,JK M'3T:DW4(=,(]4HE66,55("K`15(2'$Y&S\;4LVE\".JX.OVKY61*`RA$4YTT M(5T<(52PIH&,D2<.S`AGP`(J^M+
[7O=\L(R_I1TU[0J+ZO8/[7U\!_,)#`:H MZ:A[-0J+XOK_`-0Q>7@<#@N1Q.(&*L2NEB$%O9#7!>U]ZR:"VK=P_K?K7K,8 M/!X)17C"N-
X,&E.]=REB(KVW`\FI#6$\S2&P0LY';5T*B^+Z_]0QT MI::]H5%\7U_ZACA2^[D_(WV[Q\Z<>#WT7ZB?>IYC("TI::]H5%\7U_ZACI2T MU[0J+XOK_P!0QPI?=R?
D;[=X^=./![Z+]1/O4\QD#Z4M->T*B^+Z_P#4,=*6 MFO:%1?%]?^H8X4ONY/R-]N\?.G'@]]%^HGWJ>8R!]*6FO:%1?%]?^H8Z4M-> MT*B^+Z_]0QPI?=R?D;
[=X^=./![Z+]1/O4\QD#Z4M->T*B^+Z_\`4,=*6FO: M%1?%]?\`J&.%+[N3\C?;O'SIQX/?1?J)]ZGF,@?2EIKVA47Q?7_J&.E+37M" MHOB^O_4,
<*7W/G3CP>^B_43[U/,H'L#^0?TR%M=1]/GSENR97JF.W MCM=)LU:M;3!N'+EPL<$T4&Z"3XZJRRJABD223*910X@4A1,(!DT#V!_(,J59 M?
XE9;\K@C^M75T>Y1E<#0E6#6^-B:^G*#[!_D/\`3&,K5J^)5JV=&$KEN@Y* M0P&(5=)-8I3&W%,)04*8"B)?4(AN$0]0^K.',\3U7'=R;>5C&;CD/@/Z5QY/
MX_E_5*JX[N3;RL5CF>)ZKCNY-O*QC%!T\/ITYGB>JX[N3;RL5CF>)ZKCNY-O*QC%!T\/ITYGB>JX[N3; MRL5CF>)ZKCNY-O*QC%!T\/ITYGB>J
MX[N3;RL5CF>)ZKCNY-O*QC%!T\/IT MYGB>JX[N3;RL5CF>)ZKCNY-O*QC%! MT\/ITYGB>JX[N3;RL5CF>)ZKCNY-O
M*QC%!T\/ITYGB>JX[N3;RL5CF>)ZK MCNY-O*QC%!T\/ITYGB>JX[N3;RL5C MF>)ZKCNY-O*QC%!T\/ITYGB>JX[N3;RL5CF>)ZKCNY-

O*QC%!T\/ITYGB>JX[N3;RL5CF>)ZKCNY-O*QC%!T\/ITYGB>JX[N3;RL5CF>)ZKCNY-O*QC%!T\/ITYGB>JX[N3;RL5CF>)ZKCNY-
O*QC%!T\/ITYGB>JX[N3;RL5CF>)ZKCNY-O*QC%!T\/ITYGB>JX[N3;RL5CF>)ZKCNY-O*QC%!T\/ITYGB>JX[N3; MRL/]JVAY'_M_]17_V3_ ` end "